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Transcription factorIdentiﬁcation of transcription factor (TF) activities associated with a certain physiological/experimental
condition is one of the preliminary steps to reconstruct transcriptional regulatory networks and to identify
signal transduction pathways. TF activities are often indicated by the activities of its target genes. Existing
studies on identifying TF activities through target genes usually assume the equivalence between co-
regulation and co-expression. However, genes with correlated expression proﬁles may not be co-regulated.
In the mean time, although multiple TFs can be activated coordinately, there is a lack of efﬁcient methods to
identify coordinately activated TFs. In this paper, we propose an efﬁcient algorithm embedding a dynamic
programming procedure to identify a subset of TFs that are potentially coordinately activated under a given
condition by utilizing ranked lists of differentially expressed target genes. Applying our algorithm to
microarray expression data sets for a number of diseases, our approach found subsets of TFs that are highly
likely associated with the given disease processes.rsity of Central Florida, 4000
407 823 5835.
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Identifying potentially activated transcription factors (TFs) under
a speciﬁc experimental condition is one of the key steps in
elucidating condition-dependent signal transduction pathways and
in identifying regulatory mechanisms. Signal transduction pathways
reﬂect complex biological processes during which cell converts one
signal to another. The activation of these pathways often activates
related TFs, which then bind to their target genes at the transcription
factor binding sites (TFBSs) to turn on/off various transcription
programs. TFs activated as a result of a signal transduction cascade
can, in turn, activate more genes. Thus, activation of TFs often
indicates the activation of corresponding signaling transduction
pathways. Aside from the importance of the identiﬁcation of TF
activities in the study of signaling pathways, understanding the
differential activation of TFs under different experimental conditions
will also facilitate the study of transcription regulation and gene
regulatory network reconstruction.
Microarray experiments can measure hundreds of thousands of
genes' expression under many experimental conditions. In recent
years, dramatically increased large amount of microarray data and TF
information has been deposited into various databases [1–4].
However, it remains a challenge to identify differentially activated
TFs due to at least two issues: (i) TFs are often regulated at the post-
transcriptional level, thus it is often hard to identify TF activities by
directly measuring the expression changes of their correspondingmRNAs; and (ii) multiple TFs can be activated coordinately during the
same biological process, thus methods to identify TF activities by
identifying potential TFBSs often cannot identify the activated TFs
[5,6]. Here, coordinately activated TFs are the TFs activated under the
same condition, not necessarily those that regulate the same set of
target genes. In fact, target genes of these coordinately activated TFs
are usually so different that no TF has overrepresented binding sites in
the non-coding regions of the differentially expressed genes, which
causes many de novo TFBS identiﬁcation methods to fail in identifying
any true TFBSs. In this paper, we propose a novel algorithm to resolve
the above issues and to identify potentially activated TFs from
microarray expression data and known TF information.
Towards resolving the ﬁrst issue (i.e., the difﬁculties in directly
assessing TF activities), we aim to indirectly assess TF activities from
the activities of their target genes. There are at least two methods to
measure the activities of TF target genes. One commonly usedmethod
is to measure the degree of co-expression of the target genes by
assuming that the target genes of the same TFs often show similar
expression patterns [7,8]. The activity of a TF can be subsequently
identiﬁed from the co-expression pattern of its target genes. For
example, Petti and Church [8] identiﬁed coordinately activated
functional modules from gene expression data assuming that if a TF
inﬂuences the expression of its target genes, their expression proﬁle
will differ from that of non-target genes in the same functional
module. By assuming that co-expression indicates co-regulation,
many studies have identiﬁed TFs from genes with strongly correlated
mRNA expression proﬁles [6,9,10]. Research based on the assumption
of this relationship between co-regulation and co-expression has
provided insights on various gene regulatory mechanisms. However,
co-regulated genes are not always co-expressed, especially in
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[11]. An alternativemethod to determine differentially activated TFs is
based on identiﬁcation of differentially expressed TF target genes. The
assumption is that if the target genes of a TF are differentially
expressed, it is most likely that the TF is differentially activated. In this
paper, we adopted the second method. To determine whether a gene
is differentially expressed under two given conditions, common
methods use gene expression fold change or differential test statistic
p-value with multiple test correction [12]. However, both the fold
change and the differential test p-value have their limitations and
may not identify any differentially expressed genes in spite of their
existence [13,14]. To overcome these limitations, methods based on
gene ranking have been developed [13,15,16]. These gene ranking
methods do not establish a threshold to explicitly deﬁne differentially
expressed genes. Instead, they rank all genes according to a certain
statistic and deﬁne genes at the top positions in the ranked list are
more likely to be differentially expressed than those at the bottom.
Toward resolving the second issue, we developed a new algorithm
to simultaneously identify a subset of coordinately activated TFs from
microarray expression data. To simplify our explanation, we assume
that we have two-condition microarray experimental data, and we
can rank genes in terms of the difference of their expression proﬁles
under the two experimental conditions. Our basic assumption here is
that if a subset of TFs is simultaneously associated with a given
experimental condition, these TFs should be responsible for a
maximal number of top ranked differentially expressed genes. Based
on our assumption, we start with documented gene targets and
existing knowledge, and formulate the problem as: given a gene list
ranked by the genes expression differences between two conditions,
to identify the smallest subset of TFs that can explain the expression
differences between two conditions of as many top ranked TF target
genes as possible. Fig. 1 shows themajor steps of our algorithm, which
are detailed in the Algorithm section (The ACTIVETF algorithm to
identify coordinately differentially activated TFs). By applying our
algorithm to three microarray gene expression data sets (including an
essential thrombocythemia (ET) data set, a breast cancer data set and
a lung data set), we demonstrated the efﬁciency and efﬁcacy of our
algorithm.Fig. 1. ACTIVETF algorithm pipeline for identiﬁcation of a subset of TFs, which are cAlgorithm
As mentioned above, we determine differentially activated TFs
from their differentially expressed target genes. Instead of explicitly
deﬁning differential expression, we rank genes to estimate differential
expression. After we generate a ranking gene list, we apply a novel
algorithm ACTIVETF to identify coordinately differentially activated
TFs (Algorithm 1 described in The ACTIVETF algorithm to identify
coordinately differentially activated TFs below). The input of the
algorithm includes a given microarray gene expression data set, a
ranking gene list and known TF target gene information (for details on
this data collection, see Results). It should be noted that the
downloaded TF target genes are only target gene candidates because
a TF may bind with different subsets of its target gene candidates
under different conditions.
The ACTIVETF algorithm to identify coordinately differentially
activated TFs
Fig. 1 illustrates the major components of our algorithm. Brieﬂy,
the algorithm ﬁrst determines TFs which have signiﬁcantly larger
number of target genes in the top ranked k genes compared with the
rest of the genes. In this way, TFs with large number of target genes
uniformly distributed in the ranked gene list are ﬁltered out, and only
those TFs with their target gene distribution bias toward top ranked
genes will be retained for the next step. A dynamic programming
procedure is then performed to determine the maximal number of
genes in the top k genes that are the target genes of different
combination of given TFs. The minimal number of TFs that can explain
as many genes among the top k as possible are then chosen using a
Poisson process based statistical method. The process is repeated by
permuting k from 1 to κ, the maximal number of genes under
consideration, to identify the best subset of TFs. Each step of the
algorithm is detailed in the following subsections.
Algorithm 1. ACTIVETF(D, L, TFs, targets). Input: a microarray
expression dataset D, a ranking gene list L, the TFs and their target
genes “targets”oordinately, and differentially activated under given experimental conditions.
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top ranked genes
1. For the top k genes, where k is from 1 to κ,
(a). select nk TF candidates with many top ranked genes as
candidate target genes by a hypergeometric test;
(b). from nk TF candidates obtained from 1a, use dynamic
programming to identify the size-j TF subset that can best explain
the given top k genes (j is any number from 1 to nk);
(c). from the dynamic programming solution obtained in 1b, use
the MINTF algorithm (described in Identiﬁcation of the TF subset
that best explain the top k ranked genes) to identify the best size j,
and consequently deﬁne the corresponding subset of TFs as the TF
subset that best explain the top k ranked genes.
2. Output the subset of TFs that best explain the top k ranked genes by
selecting the best k.
Identiﬁcation of TF candidate sets
Step 1a of the ACTIVETF algorithm is a data ﬁltering process during
which we select the candidate sets of TFs that have relatively more
target genes at the top of the rank list compared with the entire rank
list. This process ﬁlters out TFs with target genes uniformly
distributed across the list, and retains TFs with many top ranked
genes as target gene candidates. To determine whether a given TF has
signiﬁcantly more target genes with ranks smaller than k, we ﬁrst
obtain the rank of the TF's target genes, and then we perform
hypergeometric test as following. Assuming that the TF has M target
genes out of the N genes in the microarray experiments, andm target
genes with rank smaller than or equal to k, the hypergeometric test p-
value of observing m or more genes within the top k list can be
deﬁned by the following formula:
Xmin k;Mð Þ
i=m
CiMC
k − i
N − M
CkN
; where Cyx =
x x − 1ð Þ: : : x − y + 1ð Þ
y y − 1ð Þ: : :1
TFs with large p-values are then ﬁltered out and only TFs with
small p-values (pb0.01/615) are chosen for further investigation. In
our experimental study described in Results, we used 0.01, a
conventional p-value cutoff, to deﬁne small p-values. For example, if
a TF had a p-value after Bonferroni correction smaller than 0.01 (i.e.,
p-valueb0.01/615), we retained this TF as a candidate.
Identiﬁcation of the size-j TF subset that can best explain the given top
k genes
In the previous step, the process of selecting one TF candidate is
independent from identifying another TF candidate. To gain a global
view of coordinately activated TFs, in step 1b of the ACTIVETF
algorithm, we aim to identify the maximal number of top k ranked
genes that are the target genes of any j out of nk TFs. We design a
dynamic programming solution for this problem, which is detailed
below. The sub-problem in the dynamic programming is to calculate S
(i,j), the maximum number of top k genes that are the target genes of
any j out of i TFs. Assuming that TF i has pi target genes among the top
k genes, we use the following recurrence to tabulate this function by
generating the values S(i, j) with the initialization S(i,j)=0 for i=0,
jb=0 and S(i,j)=-inﬁnity for i=0,jN0:
S i; jð Þ = max S i − 1; jð Þ; S i − 1; j − 1ð Þð Þ + piÞ ia 1;nk½ 
The above recursion formula states that to calculate the maximum
number of top k genes that are the target genes of j out of i TFs (i.e., the
S(i,j)), wewill either include TF i or not. If we use TF i, thenwe obtain S
(i,j) by summing the maximum number of top k genes that are the
target genes of i−1 TFs (i.e., the S(i−1, j−1)), and the number of
target genes of TF i (i.e., the pj). Otherwise, S(i,j) is equal to S(i−1,j).
For further information on dynamic programming, refer to [17].Note that different TFs may share the same target genes. In the
above recursion, if TF i shares some top ranked target genes with
other i−1 TFs, we have over-counted the number of target genes. To
solve this problem, we makem copies of a gene that is the target gene
ofm out of the nk TFs and then assign a weight 1/m to each copy. That
is, each copy of the same genes is counted as 1/m instead of 1.
The above dynamic programming will generate an nk by nk table S,
in which the j-th entry of the last row, represented as (nk,j), stores the
maximal number of genes among the top k genes that are the target
genes of j TFs. We can then backtrack from entry (nk,j) to identify the
best combination of j or fewer TFs to explain the top ranked genes.
Thus, from step 1b, for any given k and j, we can obtain a TF subset
containing j TFs that best explain the top k ranked genes. However,
we still need to determine what the best j is. We deﬁne the number of
identiﬁed TFs, represented as j, as the best number of TFs if the
addition of one more TF will not add many more target genes ranked
at the top k locations. Here, we design a Poisson process to identify the
best number of TFs.
The Poisson process is used to describe the number of events
occurring in a time interval. Because the number of top target genes
increases with the increment of the number of TFs, Poisson process is
a good null model to detect abnormally slow increments of the
number of top target genes with the increment of the TF number. Here
we model the number of TFs j as the time interval and the number of
target genes of the j TFs as the number of events that occurred in the
time interval [0, j].
Identiﬁcation of the TF subset that best explain the top k ranked genes
Based on the above discussion, at Step 1c of the ACTIVETF
algorithm, we use the MINTF algorithm (described in Algorithm 2)
to determine the best number of TFs, and consequently the best
subset of TFs, that we should choose to explain as many top ranked
genes as possible. The MINTF algorithm is detailed as follows. Assume
that we are considering the top kmost differentially expressed genes,
and we have S(nk,j) describing the number of genes out of the top k
ranked genes that are target candidates of j TFs. In Step 1 of the MINTF
algorithm, we will ﬁnd the smallest j such that S(nk,j+1)−S(nk,j)b1.
This step implies that a chosen TF has at least one top ranked gene as
its target gene candidate. In Step 2 of the MINTF algorithm, we
estimate the rate parameter of the Poisson Process by λ=S(nk,j)/j,
which represents the average number of top target genes explained
by one TF alone. According to statistics theory, S(nk,j)/j is a good
estimate of λ because it is the maximal likelihood estimate of the rate
parameter. In step 3 of the MINTF algorithm, we calculate the p-value
of observing S(nk,j) target genes of j TFs that rank in the top k (S(nk,
j)∼Poisson(λ× j)). Note that the expected number of target genes
among the top k genes is λ× j if j or fewer TFs are selected. We then
output the largest j such that the corrected p-value is less than the
pre-deﬁned threshold, say jk⁎. From the algorithm description, we can
obtain the time complexity for MINTF algorithm as Θ(nk) where nk is the
number of TF candidates obtained from the above hypergeometric tests
for top k ranked genes.
Algorithm 2. MINTF(S, k). Input: S is the table generated by the
dynamic programming for the top k differentially expressed genes
Output: the minimal number of TFs that best explain the top k
differentially expressed genes.
(1) Identify the smallest j such that S(nk,j+1)−S(nk,j)b1.
(2) Deﬁne the Poisson parameter λ=S(nk,j)/j.
(3) Calculate the p-value of observing S(nk,i) events under the
assumption that S(nk,i) is a Poisson random variable with
parameter λ× i, for i from 1 to j. Output the largest i such that
the p-value is less than 0.01/κ/n, where n is the number of TFs
under consideration.
Table 1
TFs and their target genes differentially activated under two stage experimental
conditions for ET.
TF Top Target genes
HSF1 FSTL3, TLK1, PIM1, PPT2, RIMS2GAD2, STX12, ELAVL4,
CISH, A2BP1, MORF4L2, CBX3, SOCS2, NR4A3, PHF6,
E2F3, FOS, EGR3, OTX2, TRIB1
HIF1 LDHA, CITED2, PTPRF, PIM1, PPT2, PPP1R3B, RWDD2A
P4HA1, PROK2, PRKAR2A, SLC2A1, ITCH, ARNTL, XRN2,
AK3, E2F3, TIMM10
GATA, SPAG9, PCF11, PPT2, NPL, KCNH5, ZFP36L1, PNLIPRP1,
ELAVL4, KHK, TOB1, BTRC, GATA1, SLC2A1, MYL7, EYA1,
TSHB, HIC1, PTPRC, NCDN
Table 2
TFs and their target genes differentially activated under two stage experimental
conditions for breast cancer.
TF top Target genes
ZEB1 SEMA3F, FUT8, DMXL1, SCUBE2, NPEPPS, SSH3, FOXA1
IRF1 GATA3, FOXA1, SALL2, ESR1, SH3BGRL
LEF1 FOXA1, CLSTN2, ARL3, FUT8, APBB2, DMXL1, SH3BGRL,
MAGED2, ERBB4, GFRA1, CACNA2D2, DACH1, CISH,
SCUBE2, CA12
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minimal number of TFs that may regulate the maximal number of
target genes among the top k genes. In step 2 of the ACTIVETF
algorithm, we will output the best set of TFs by selecting the best k. To
do this, we iterate k from 1 to κ to identify the best subset of TFs that
explains the activity of themost target genes with rank smaller than k.
This will result in κ tables generated by dynamic programming. By
applying the MINTF algorithm on each of the κ tables, we obtain best
jk⁎ TFs for κ different setups of k. We then choose the subset of TFs
that maximize s(nk, jk⁎)/(k×jk⁎) for all k. Let j⁎=arg max (S(nk, jk⁎)/
(k×jk⁎)),weoutput the j⁎ TFs as thepotential activated TFs. Note thatwe
divide k in the formula because the smaller k is, themore likely it is that
the k top genes are differentially expressed and thus the j⁎ TFs are most
likely activated. Thus, the j⁎ TFs selected are more likely to be active.
In summary, the ACTIVETF algorithm delineated in the Algorithm 1
combines dynamic programming with a statistical method to identify
a minimal number of TFs that may coordinately regulate the maximal
number of top ranked genes. ACTIVETF is a very efﬁcient algorithm.
When k is smaller than a speciﬁed threshold κ, say κ=1000, the
algorithm has a linear time complexity. If we allow k to be any
number, then this is a quadratic algorithm with complexity Θ(knk)
where nk is the maximal number of TFs output from the hypergeo-
metric tests.
Results
Data collection
We collected three microarray data sets. The essential thrombo-
cythemia (ET) data set [11] consists of samples from 16 patients, nine
have the JAK2 V617F mutation and seven do not. The breast cancer
data set [12] consists of samples from 286 patients, 209 are ER positive
and 77 are ER negative. The last dataset is the Michigan group lung
data set [13], consisting of samples from 86 patients, 24 had poor
outcome and 62 of 86 patients had good outcome. For these
microarray data sets, we ﬁrst classiﬁed all of the samples into two
relevant conditions. For example, for the breast cancer data set, we
group samples corresponding to ER positive and ER negative
respectively. We next utilized a differential t test to determine
whether a gene is differentially expressed between the two relevant
conditions. The differential test is able to assign each gene a p-value.
All of the genes are then ranked according to this p-value.
As mentioned in Algorithm, we collected 615 TF target gene sets
from the mSigDB database (C3: motif gene sets) [15]. This TF target
gene data was originally collected from curated data in the TRANSFAC
database [18] and/or predicted by comparative genomics approaches
[19]. Each of these gene sets contains genes that share a TFBS deﬁned
in the TRANSFAC, and each of these gene sets is annotated by a
TRANSFAC record. Note that the TF target genes used here are
incomplete. In the future, with more complete and more accurate TF
target gene data, more complete picture of transcription programs
under speciﬁc conditions can be generated by applying the developed
method.
Experimental study
We applied our algorithm to the ET dataset and identiﬁed three
known TFs corresponding to heat shock transcription factor 1 (HSF1),
Hypoxia-inducible factor 1 (HIF1) and GATA binding protein (GATA)
(Table 1). We know that ET is one type of the myeloproliferative
disorders and is characterized with increasing bone marrow mega-
karyocytes and persistent thrombocytosis. It has been shown that
HIF1 controls angiogenesis and glycolysis and is closely related to
myeloproliferative disorders [20]. Increased angiogenesis is also
found in the bonemarrow (BM) of leukemias. Immunohistochemistry
has shown that HIF1 is overexpressed in clusters of leukemic cells inBM specimens of childhood acute lymphoblastic leukemia (ALL) and
absent in biopsies of normal BM [21]. GATA1 is a haemopoietic factor,
and many studies have implicated GATA1 in the pathogenesis of both
thrombocytopenia and myeloproliferation [22–26]. It is interesting to
note that both GATA and HSF1 are co-listed here, because it has been
shown that HSF1 does not co-localize with members of the GATA
family, and thus compartmentalization of the two TFs is not very likely
[27]. In addition, HIF1 can bind to TFs that recognize GATA, and HIF1A
is also able to form complexes with GATA [28]. Therefore, the three
predicted coordinately activated TFs do participate in ET-relevant
biological processes.
We then tested our algorithm on the breast cancer data. We
identiﬁed three signiﬁcant TFs corresponding to zinc ﬁnger E-box
binding homeobox 1 (ZEB1), interferon regulatory factor 1 (IRF1),
and lymphoid enhancer binding factor 1 (LEF1) (Table 2). The
literature shows that these three predicted TFs are coordinately
activated in breast cancer. For example, ZEB1 is also known as ZEB1
and TCF8, which encodes a zinc ﬁnger TF. The relevance of ZEB1 to
breast cancer has been shown in a number of studies [29,30]. ZEB1,
together with SNAI1, has been hypothesized to be a downstream
target of WISP3 and to play a critical role in WISP3-mediated
regulation of CDH1 in breast cancer [30]. LEF1, a downstream
component of the Wnt signaling pathway, has been reported to
mediate breast cancer cell invasion [31]. Both ZEB1's and LEF1's
expression can be induced by the SNAI1 homolog 1 (SNAI1) gene
[32]. Preliminary information from expression microarray data sets
from primary human breast cancers suggests that high levels of SNAI1
are correlated with poor clinical outcome for women with early
breast cancer. Moody et al. [33] identiﬁed the association between
SNAI1 gene expression and clinical outcomes from four published
primary breast cancer microarray data sets, and suggested that SNAI1
expression predicts poorer relapse-free survival independently of
other prognostic markers. In addition, IRF1 has also shown tumor
suppressor activities in breast cancer [34–36].
We also analyzed the lung cancer data set. We identiﬁed two
signiﬁcant TFs (Table 3). Their corresponding genes are MYC-
associated zinc ﬁnger protein (MAZ) and v-ets erythroblastosis virus
E26 oncogene homolog 2 (ETS2). It is known that ETS2 and MAZ are
both cancer related oncogenes [37,38].
The results described above demonstrate that these simultaneous-
ly identiﬁed TFs are all involved in their corresponding disease
Table 3
TFs and their target genes differentially activated under two stage experimental
conditions for lung cancer.
TF top Target genes
ETS2 SPIB, IL7R, PTK7, CDKN1A, CD6, CD247, PRKACB,
ITGAL, PTPRCAP, PPIF, CD79A, GFI1, PIK3R1, GNG11,
TRIP10, LCK, STAT4, RUNX3, PTPN7, NPAS2, CRK
MAZ C4A, SPIB, GAPDH, FMO2, FMO3, ADORA2A, PTK7,
CDKN1A, KLF10, UGP2, LCAT, CCR7, FYN, VEGFA, LCK,
DBP, BCAT2, RUNX3, PTPN7, CNN3, CTNND2, DAXX,
BCAM, RNF5, PLA2G7, CORO1A, SLC5A2, HRC, TRIP10,
SLC2A1, GPC3, ANXA6, H2AFZ, WNT5A, NPAS2
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extracted data for the identiﬁed TFs and their target genes from the
protein-protein interaction network downloaded from the Human
Protein Reference Database (HPRD) (Fig. 2a). Fig. 2a shows that CREB
binding protein (CREBBP) can interact with all three TFs identiﬁed
from the ET data set. Because CREBBP is an important member in the
JAK-STAT pathway, and the given phenotype is related to a JAK2
mutation, this result further supports the association of identiﬁed TFs
with the given phenotype. Fig. 2b shows the extracted PPI subnetwork
corresponding to the identiﬁed TFs and their target genes from the
breast cancer data. It can be seen that the three identiﬁed TFs are
connected by a dense protein subnetwork centering on the estrogenFig. 2. PROTEIN interaction network formed by transcriptions factors (circled in dashed line
Michigan lung data set (Figure drawn with PAJEK software [41]).receptor 1 (ESR1) gene. Because ESR1 is well known to be involved in
the pathological processes of breast cancer, the three TFs may be
activated coordinately through the same ESR-related mechanism. In
Fig. 2c, the potential interaction between the two identiﬁed TFs from
lung cancer data is presented.
We further calculated the expression correlation between the
identiﬁed TFs and their target genes using Pearson's correlation. As
expected, we found that TFs are often not correlated well with their
target genes. Fig. 3 illustrates the distribution of correlation between
identiﬁed TFs and their target genes (Figs. 3a, c, e). Only 29% of
correlations between a TF and its target genes have a correlation value
above 0.2, and none of these correlations is above 0.35. In comparison,
target genes have better correlations with each other, as shown in the
scatter plots of the distributions (Figs. 3b, d, f). However, there is still
no rule observed showing target genes to have high correlation. In
fact, Fig. 3 shows that a large percentage of target genes have
correlations below 0.2. This conﬁrms the limitation of using co-
expression between TFs and their target genes to identify differen-
tially activated TFs.
Comparisons with other methods
Currently, no existing method can be directly applied to identify a
subset of TFs which are coordinately differentially activated under
speciﬁc conditions. However, several methods have been developed) and their target genes, identiﬁed from (a) ET data set; (b) breast cancer data set; (c)
148 H. Hu / Genomics 95 (2010) 143–150to identify phenotype-relevant genes or gene sets. Gene set
enrichment methods such as GSEA are examples of such methods
[13,15,16,39,40]. Although these methods are not developed for the
purpose of identiﬁcation of differentially activated TFs, we can apply
thesemethods to indirectly identify conditionally activated TFs. Below
we will detail how we use the GSEA-like methods to identify
differentially activated TFs and how the GSEA-like methods perform
in comparison with our developed method.
GSEA ranks all genes based on the phenotypic relevance, and
calculates a score that reﬂects the degree to which a given set of genes
is represented at the extremes of the entire ranked list. The score is
calculated by walking down the list of genes ordered by expression
change. The score is increased for every gene that belongs to the given
gene set and decreased for every gene that does not. The input gene
set for the GSEA is often a set of genes with prior annotation, for
example, a set of genes that share common biological function,
chromosomal location, or regulation, or a set of known genes in an
annotated pathway. Therefore, GSEA in fact can score the phenotypic
relevance of a priori deﬁned set of genes. Thus, one may deﬁne TFFig. 3. Scatter plot of Pearson's correlation coefﬁcients between identiﬁed TFs and their targe
x axis in a, c, e represents the index of target genes corresponding to a given TF. The x axis in b
(a–f) represents the Pearson's correlation coefﬁcients.target genes as the input gene set, and then apply GSEA to determine
the activities of a given TF.
Here we compare our method with the above described GSEA
based methods to identify TF activities. By considering all of the target
gene candidates corresponding to one transcription factor as one gene
set, we are able to apply GSEA methods to test the enrichment of a set
of target genes corresponding to a TF. As a result, we found no
signiﬁcantly enriched TF target gene sets in general. For example, for
the ET dataset, all three target gene sets corresponding to the HSF1,
HIF1 and GATA TFs were assigned FDR q-value=1. HSF1 had a p-
value=0.083, HIF1 had a p-value=0.02268 and GATA had a p-
value=0.2633. This is not unexpected because ﬁrst, a TF target gene
set downloaded frommSigDB only contains target gene candidates for
one TF. Thus, many of these target gene candidates are not the real
target genes under the given conditions. However, when we applied
GSEA using all target gene candidates for one TF as the input gene set,
we had noway to tell whether a target gene candidate is a true or false
target gene. Thus, considering all of the genes in a target gene set as
real targets may not reveal any differentially activated TFs. Moreover,t genes, and between identiﬁed target genes themselves (From breast cancer data). The
, d, and f represents the index of target gene pairs corresponding to a given TF. The y axis
149H. Hu / Genomics 95 (2010) 143–150from the GSEA procedure of considering input gene sets one at a time,
there is no way to utilize the potential constraints generated by
multiple TF activations and thus there is no way for the GSEA method
to generate a subset of coordinately, differentially activated TFs.
Discussion and conclusion
To identify the minimal subset of coordinately differentially
activated TFs is a challenging problem. First, even if target genes of
an activated TF are most likely to be differentially expressed, it is hard
to determine which genes are the target genes of a TF under the given
experimental conditions without a way to explicitly deﬁne differen-
tially expressed genes. Additionally, because multiple TFs can be
activated coordinately under the given conditions, methods that
consider individual TF activities one at a time or dummymethods that
simply choose several TFs with the most target genes in top ranked
genes will only obtain suboptimal solutions. In this paper, we
developed a novel algorithm, to simultaneously identify a subset of
TFs that are potentially activated under a given experimental
condition. We assume that if a subset of TFs is coordinately activated
under a given experimental condition, these TFs should be responsible
for a maximal number of top ranked differentially expressed genes.
Based on our assumption, our method begins with ranking the
differentially expressed genes from collectedmicroarray experiments.
Then, a dynamic programming procedure is iteratively applied, and a
Poisson process-based statistical method is used to identify the best
subset of potentially activated TFs for each speciﬁed k top ranked
differentially expressed genes. The algorithm iterates over k from 1 to
κ, the maximal number of genes under consideration, and output the
best subset of TFs to explain the top ranked genes.
We compared our method with GSEA to identify TF activities. Two
difﬁculties are encountered when applying GSEA. One is the difﬁculty
in deﬁning a TF's target genes. As we know, TFs bind different target
genes under different experimental conditions. Assuming differen-
tially expressed target genes are more likely to be bound by their
corresponding TFs, one cannot explicitly deﬁne differentially
expressed genes from ranked gene list and thus cannot explicitly
deﬁne which target gene candidates are real target genes. The other
problem when using GSEA to deﬁne TF activities is that multiple TFs
are often coordinately activated, but GSEA can only test one gene set
at a time and thus cannot output multiple phenotype-relevant gene
sets simultaneously. Because GSEA-based methods neglect interde-
pendency between various transcriptional activation mechanisms,
they often provide non-optimal solutions. In comparison with gene
set enrichment-based methods, our approach has two unique
advantages. One advantage is that, by considering activities of TFs
simultaneously, our approach can systematically identify coordinately
activated TFs. It is important to incorporate interdependency into the
identiﬁcation process to provide insight into TF regulatory mechan-
isms. The other advantage is that, as a side product, our program also
identiﬁes conditional TF target genes due to the coupling of
identifying activated TFs and identifying their differentially expressed
target genes. It is well known that TFs bind to different target gene
candidates under different conditions. Our algorithm deﬁnes TFs from
top ranked target gene candidates and deﬁnes top ranked TF target
genes from identiﬁed activated TFs. Thus, when we output the
coordinately differentially activated TF subset, we can simultaneously
output the top ranked target genes used during the identiﬁcation
process.
We applied our algorithms to a number of disease microarray data
sets and identiﬁed activated TF subsets associated with the given
disease phenotype. Many of the discovered TFs are supported by
previous research. When we projected the identiﬁed TFs and their
target genes into protein interaction networks, we can clearly saw the
possible coordination among the TFs. Thus, our methods can be
extended to assist in further generating biological hypotheses onregulatory mechanisms and disease pathogenesis. Also, the generated
subset of activated TFs can be further studied to identify their
corresponding signal transduction pathways or to identify gene
transcription regulation switches under speciﬁc conditions.
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